Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Larry Moreland, Ron Gugliotti, Kevin King, Walter Chase, Michael Weisman, Thomas Greco, Rose Fife, Joseph Korn, Robert Simms, John Tesser, Jan Hillson, Jacques Caldwell, Thomas Schnitzer, David Lyons, Ullrich Schwertschlag

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide production. In animal models of arthritis, treatment with recombinant human IL-11 (rhlL-11) reduces both the level of synovitis and the histologic lesion scores in the joints. The goal of this phase-I/II study in adults with rheumatoid arthritis (RA) was to evaluate the safety and clinical activity of different doses and schedules of rhlL-11 in patients with active RA for whom treatment with at least one disease-modifying antirheumatic drug had failed. This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of rhIL-11 in 91 patients with active RA. rhIL-11 was administered subcutaneously; patients were randomized into one of five treatment groups (ratio of rhIL-11 to placebo, 4:1). Patients were treated for 12 weeks with either 2.5 or 7.5 μg/kg of rhIL-11 or placebo twice per week or 5 or 15 μg/kg of rhlL-11 or placebo once per week. The status of each subject's disease activity in accordance with the American College of Rheumatology (ACR) criteria was assessed before, during, and after completion of administration of the study drug. Administration of rhIL-11 was well tolerated at all doses and schedules. The most frequent adverse event was a reaction at the injection site. The data suggest a statistically significant reduction in the number of tender joints (P< 0.008) at the 15 μg/kg once-weekly dose schedule but showed no overall significant benefit at the ACR criterion of a 20% response. The trial showed rhIL-11 to be safe and well tolerated at a variety of doses and schedules over a 12-week treatment period in patients with active RA. The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site.

Original languageEnglish
Pages (from-to)247-252
Number of pages6
JournalArthritis Research
Volume3
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Interleukin-11
Rheumatoid Arthritis
Placebos
Appointments and Schedules
Therapeutics
Joints
Cytokines
Safety
Injections
Antirheumatic Agents
Synovitis
Rheumatology
Hematopoietic Stem Cells
Growth and Development
Arthritis
Nitric Oxide
Randomized Controlled Trials
Animal Models

Keywords

  • Cytokines
  • Interleukin-11
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. / Moreland, Larry; Gugliotti, Ron; King, Kevin; Chase, Walter; Weisman, Michael; Greco, Thomas; Fife, Rose; Korn, Joseph; Simms, Robert; Tesser, John; Hillson, Jan; Caldwell, Jacques; Schnitzer, Thomas; Lyons, David; Schwertschlag, Ullrich.

In: Arthritis Research, Vol. 3, No. 4, 2001, p. 247-252.

Research output: Contribution to journalArticle

Moreland, L, Gugliotti, R, King, K, Chase, W, Weisman, M, Greco, T, Fife, R, Korn, J, Simms, R, Tesser, J, Hillson, J, Caldwell, J, Schnitzer, T, Lyons, D & Schwertschlag, U 2001, 'Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis', Arthritis Research, vol. 3, no. 4, pp. 247-252. https://doi.org/10.1186/ar309
Moreland, Larry ; Gugliotti, Ron ; King, Kevin ; Chase, Walter ; Weisman, Michael ; Greco, Thomas ; Fife, Rose ; Korn, Joseph ; Simms, Robert ; Tesser, John ; Hillson, Jan ; Caldwell, Jacques ; Schnitzer, Thomas ; Lyons, David ; Schwertschlag, Ullrich. / Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. In: Arthritis Research. 2001 ; Vol. 3, No. 4. pp. 247-252.
@article{2873c24d42ea42a197d5a6da71335430,
title = "Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis",
abstract = "Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide production. In animal models of arthritis, treatment with recombinant human IL-11 (rhlL-11) reduces both the level of synovitis and the histologic lesion scores in the joints. The goal of this phase-I/II study in adults with rheumatoid arthritis (RA) was to evaluate the safety and clinical activity of different doses and schedules of rhlL-11 in patients with active RA for whom treatment with at least one disease-modifying antirheumatic drug had failed. This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of rhIL-11 in 91 patients with active RA. rhIL-11 was administered subcutaneously; patients were randomized into one of five treatment groups (ratio of rhIL-11 to placebo, 4:1). Patients were treated for 12 weeks with either 2.5 or 7.5 μg/kg of rhIL-11 or placebo twice per week or 5 or 15 μg/kg of rhlL-11 or placebo once per week. The status of each subject's disease activity in accordance with the American College of Rheumatology (ACR) criteria was assessed before, during, and after completion of administration of the study drug. Administration of rhIL-11 was well tolerated at all doses and schedules. The most frequent adverse event was a reaction at the injection site. The data suggest a statistically significant reduction in the number of tender joints (P< 0.008) at the 15 μg/kg once-weekly dose schedule but showed no overall significant benefit at the ACR criterion of a 20{\%} response. The trial showed rhIL-11 to be safe and well tolerated at a variety of doses and schedules over a 12-week treatment period in patients with active RA. The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site.",
keywords = "Cytokines, Interleukin-11, Rheumatoid arthritis",
author = "Larry Moreland and Ron Gugliotti and Kevin King and Walter Chase and Michael Weisman and Thomas Greco and Rose Fife and Joseph Korn and Robert Simms and John Tesser and Jan Hillson and Jacques Caldwell and Thomas Schnitzer and David Lyons and Ullrich Schwertschlag",
year = "2001",
doi = "10.1186/ar309",
language = "English",
volume = "3",
pages = "247--252",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

AU - Moreland, Larry

AU - Gugliotti, Ron

AU - King, Kevin

AU - Chase, Walter

AU - Weisman, Michael

AU - Greco, Thomas

AU - Fife, Rose

AU - Korn, Joseph

AU - Simms, Robert

AU - Tesser, John

AU - Hillson, Jan

AU - Caldwell, Jacques

AU - Schnitzer, Thomas

AU - Lyons, David

AU - Schwertschlag, Ullrich

PY - 2001

Y1 - 2001

N2 - Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide production. In animal models of arthritis, treatment with recombinant human IL-11 (rhlL-11) reduces both the level of synovitis and the histologic lesion scores in the joints. The goal of this phase-I/II study in adults with rheumatoid arthritis (RA) was to evaluate the safety and clinical activity of different doses and schedules of rhlL-11 in patients with active RA for whom treatment with at least one disease-modifying antirheumatic drug had failed. This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of rhIL-11 in 91 patients with active RA. rhIL-11 was administered subcutaneously; patients were randomized into one of five treatment groups (ratio of rhIL-11 to placebo, 4:1). Patients were treated for 12 weeks with either 2.5 or 7.5 μg/kg of rhIL-11 or placebo twice per week or 5 or 15 μg/kg of rhlL-11 or placebo once per week. The status of each subject's disease activity in accordance with the American College of Rheumatology (ACR) criteria was assessed before, during, and after completion of administration of the study drug. Administration of rhIL-11 was well tolerated at all doses and schedules. The most frequent adverse event was a reaction at the injection site. The data suggest a statistically significant reduction in the number of tender joints (P< 0.008) at the 15 μg/kg once-weekly dose schedule but showed no overall significant benefit at the ACR criterion of a 20% response. The trial showed rhIL-11 to be safe and well tolerated at a variety of doses and schedules over a 12-week treatment period in patients with active RA. The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site.

AB - Interleukin-11 (IL-11) is a pleiotropic cytokine that regulates the growth and development of hematopoietic stem cells and decreases the proinflammatory mediators of cytokine and nitric oxide production. In animal models of arthritis, treatment with recombinant human IL-11 (rhlL-11) reduces both the level of synovitis and the histologic lesion scores in the joints. The goal of this phase-I/II study in adults with rheumatoid arthritis (RA) was to evaluate the safety and clinical activity of different doses and schedules of rhlL-11 in patients with active RA for whom treatment with at least one disease-modifying antirheumatic drug had failed. This was a multicenter, randomized, placebo-controlled trial that evaluated the safety and tolerability of rhIL-11 in 91 patients with active RA. rhIL-11 was administered subcutaneously; patients were randomized into one of five treatment groups (ratio of rhIL-11 to placebo, 4:1). Patients were treated for 12 weeks with either 2.5 or 7.5 μg/kg of rhIL-11 or placebo twice per week or 5 or 15 μg/kg of rhlL-11 or placebo once per week. The status of each subject's disease activity in accordance with the American College of Rheumatology (ACR) criteria was assessed before, during, and after completion of administration of the study drug. Administration of rhIL-11 was well tolerated at all doses and schedules. The most frequent adverse event was a reaction at the injection site. The data suggest a statistically significant reduction in the number of tender joints (P< 0.008) at the 15 μg/kg once-weekly dose schedule but showed no overall significant benefit at the ACR criterion of a 20% response. The trial showed rhIL-11 to be safe and well tolerated at a variety of doses and schedules over a 12-week treatment period in patients with active RA. The only adverse event clearly associated with rhIL-11 administration was reaction at the injection site.

KW - Cytokines

KW - Interleukin-11

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=17844403234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844403234&partnerID=8YFLogxK

U2 - 10.1186/ar309

DO - 10.1186/ar309

M3 - Article

C2 - 11438043

AN - SCOPUS:17844403234

VL - 3

SP - 247

EP - 252

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 4

ER -